Deworming children for soil-transmitted helminths in low and middle income countries: Systematic review and individual participant data network meta-analysis

Vivian A Welch1,2\*, Alomgir Hossain2,3,4, Elizabeth Ghogomu5, Alison Riddle2, Simon Cousens10, Michelle Gaffey6, Paul Arora7,8, Robert Black12, Donald Bundy16, Mary Christine Castro17, Li Chen3, Omar Dewidar5, Alison Elliott18, Henrik Friis19, T. Déirdre Hollingsworth13, Sue Horton14, Charles H. King21, Huong Le Thi20, Chengfang Liu22, Fabian Rohner23, Emily K Rousham24, Rehana Salam9, Erliyani Sartono25, Peter Steinmann26, Taniawati Supali27, Peter Tugwell15 , Emily Webb28, Franck Wieringa29, Pattanee Winnichagoon30, Maria Yazdanbakhsh25, Zulfiqar A Bhutta11¶, George A Wells2,3¶

1Centre for Global Health, Bruyère Research Institute, Ottawa, Ontario, Canada

2School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, Ontario, Canada

3Cardiovascular Research Methods, University of Ottawa Heart Institute, Ottawa, ON, Canada

4Institute for Clinical Evaluative Sciences (ICES), University of Ottawa, Ottawa, Ontario, Canada

5Bruyère Research Institute, University of Ottawa, Ottawa, Ontario, Canada

6Hospital for Sick Children, and University of Toronto 555 University Avenue

7Public Health Agency of Canada in the National Public Health Laboratory, Toronto, Ontario, Canada

8Dalla Lana School of Public Health, University of Toronto, Ontario, Canada

9South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia

10London School of Hygiene and Tropical Medicine (LSHTM) Room 116-LSHTM Keppel Street London, UK

11Centre for Global Child Health, The Hospital for Sick Children; Center of Excellence in Women and Child Health, Aga Khan University

12Department of International Health, Johns Hopkins School of Hygiene and Public Health, 615 North Wolfe Street, Baltimore, Maryland 21205, USA

13Big Data Institute, Li Ka Shing Centre for Health Information and Discovery,  Nuffield Department of Medicine, University of Oxford, UK

14[School of Public Health and Health Systems](https://uwaterloo.ca/public-health-and-health-systems/), University of Waterloo, Waterloo, ON, Canada

15Center for Global Health, WHO Collaborating Centre for Knowledge Translation and Health Technology Assessment in Health Equity, Bruyère Research Institute, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ontario, Canada

16London School of Hygiene & Tropical Medicine, London, UK

17Nutrition Center of the Philippines, Taguig City, Philippines

18Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda

19Department of Human Nutrition, University of Copenhagen, Frederiksberg, Denmark

20Institute for Preventive Medicine and Public Health, Hanoi Medical University

21Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

22School of Advanced Agricultural Sciences (SAAS), China Center for Agricultural Policy (CCAP), Peking University, Beijing, China

23GroundWork, Hintergasse 1, 7306 Fläsch, Switzerland

24School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, UK

25Dept. of Parasitology, Leiden University Medical Center, Leiden, the Netherlands

26Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland

27Dept. Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

28Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology London School of Hygiene and Tropical Medicine, Room G12 LSHTM, Keppel Street London, UK

29UMR204 Nutripass, Institute de Recherche pour le Développement, IRD/UM/SupAgro 34394, Montpellier, France

30Community/International Nutrition, Institute of Nutrition, Mahidol University, Thailand

\* Corresponding author

Email: [vwelch@campbellcollaboration.org](mailto:vwelch@campbellcollaboration.org) (VW)

¶ ZAB and GAW are Joint Senior Authors

# Author contributions

VW, EG, AH, AR, GAW had full access to the data and take responsibility for the accuracy of data analyses.

Concept and design: ZB, MG, SC, VW, GAW, PA, and the Advisory Board (SH, RB, PT, DH, CH)

Acquisition of data: VW, EG, CM, OD, AR and all trial authors (DB, MCC, AE, HF, DH, CK, HL, CL, ES, PS, TS, FR, ER, EW, FW, PW, MY)

Drafting of manuscript: VW, EG, AR

Critical revision of content: all authors

Statistical analysis: VW, AH, AR, OD

Obtained funding: ZB, MG, SC, GAW, VW

# Abstract

## Background

Intestinal parasites affect millions of children in low and middle income countries. We aimed to assess effects of deworming on nutritional and cognitive outcomes across potential effect modifiers using individual participant data.

## Methodology/Findings

We searched MEDLINE, CINAHL, LILACS, EMBASE, the Cochrane Library, Econlit, Internet Documents in Economics Access Service, Public Affairs Information Service, Social Services Abstracts, Global Health CABI and CAB Abstracts to March 27, 2018. We searched grey literature, contacted authors and screened reviews. We included randomized and quasi randomized trials of deworming children compared to placebo or other nutritional or deworming interventions with data on baseline infection.

We used a random-effects network meta-analysis with IPD and assessed overall quality, following a pre-specified protocol. The outcomes were weight, height, haemoglobin and cognition.

We received IPD from 19 trials of STH deworming (n= 31,945). Overall risk of bias was low.

There were no statistically significant subgroup effects across age, sex, nutritional status or infection intensity for each type of STH. However, these analyses showed that children with moderate or heavy intensity *A. lumbricoides* or *T. trichiura* infections, deworming for STH may increase weight gain (very low certainty).

We updated prior systematic reviews with new data, and replicated findings of small effects on population-level weight gain.

## Conclusions/Significance

The added value of this review is exploration of effects on growth and cognition in children with moderate to heavy infections as well as replicating prior systematic review results of small effects at the population level. Policy implications are that complementary public health strategies need to be assessed and considered to achieve growth and cognition benefits for children in helminth endemic areas. This review is limited by short study durations and that IPD could only be retrieved from half of the eligible trials. We also encourage adoption of Open Data to maximize the societal benefit of research for the most vulnerable populations.

**Funding**: Bill and Melinda Gates Foundation

**Registration**: The protocol for this systematic review was peer-reviewed and published with the Campbell Collaboration.

# Author Summary

Mass deworming has been a cornerstone of development programs for many years. However, recent systematic reviews have shown small effects on nutritional outcomes at a population level and reached discordant conclusions about the importance of prevalence of infections. We collected individual participant data from all eligible studies to assess whether the small effects at population-level were explained by subgroup effects in vulnerable populations with poorer nutritional status or heavier intensity infections.

We used a network meta-analysis approach which allows the comparison of different combinations of deworming with micronutrients and iron. Our findings suggest that effects of deworming on weight gain may be larger in children with moderate to heavy intensity infections, based on very low certainty evidence. We also identified new studies and added these to prior meta-analyses, which replicate prior findings of small average effects of deworming on nutritional outcomes and no effect on cognitive outcomes.

A limitation of this review is that almost half of eligible studies could not be retrieved due to the burden of sharing data and lost data. Thus, we emphatically support the urgent need for much wider adoption of Open Data to facilitate analyses such as these aimed at understanding benefits for the most vulnerable populations.

# Introduction

In 2014, over 800 million people were infected with soil transmitted helminths (STH) and water-borne schistosomes(1). Mass deworming has been described as one of the most cost-effective development interventions(2). The WHO 2017 guidelines recommend annual or biannual mass deworming for children, to be accompanied with hygiene and water interventions(3).

Two recent systematic reviews on mass deworming for soil transmitted helminths concluded there was little to no effect on nutritional status, cognition or school attendance(4, 5). These reviews did not find evidence of subgroup effects across intensity of infection, prevalence, nutritional status or sex. In contrast, a different meta-analysis found larger effects for weight in areas with higher prevalence of STH infections(6).

These previous assessments of effect modification assessed the relationship between effects of deworming to study-level average infection prevalence, which may be confounded by other study-level characteristics (e.g. food security, other NGO programs). The question of whether deworming has greater effects on child nutritional and cognitive outcomes in areas with higher prevalence and intensity of infections is important for policy to focus deworming where it is most needed and likely to have the largest impact.

We aimed to explore the importance of effect modifiers using individual participant data (IPD). IPD allows all outcomes to be converted to a common metric, allows adjustment for potential confounders and provides better power to assess subgroup effects([7](#_ENREF_7)). Because concurrent interventions are often given in studies of deworming, we used a network meta-analysis approach which has greater power to compare different treatments which may not have been directly compared.

# Methods

We conducted a systematic review and network meta-analysis of individual participant data (IPD). Network meta-analysis (NMA) is an approach which compares effects of multiple interventions using evidence from trials which have directly compared them as well as estimating indirect effects for interventions which have not been compared to each other in a trial([8](#_ENREF_8)). NMA has been described as the “next generation” of evidence synthesis because it increases the precision of effect estimates for direct comparisons and allows comparisons of interventions which may not have been directly compared([8](#_ENREF_8)). The use of IPD further strengthens the approach leading to decreases in heterogeneity within comparisons and improving overall network consistency because it accounts for effect modification at the individual participant level and missing data can be addressed([9](#_ENREF_9)).

We report results according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) extensions for network meta-analysis (NMA)([10](#_ENREF_10)) and IPD([11](#_ENREF_11)). The protocol was published with the Campbell Collaboration([12](#_ENREF_12)). Deviations from the protocol are described in S1 Appendix.

## Search strategy and selection criteria

We included randomized and quasi-randomized controlled trials of deworming for STH (including *Ascaris lumbricoides*, *Trichuris trichiura* and hookworm) or schistosomiasis in children 0.5 years to 16 years of age, with duration of four months or more. We included studies of mass deworming as well as those which screened for infection. We included nutritional co-interventions and comparisons with other deworming or nutritional interventions. We excluded studies with less than 100 participants since the Advisory Board and team felt the additional effort to trace these studies would have a limited contribution to the evidence network. We excluded studies that did not measure baseline infection intensity of STH.

We searched up to March 27, 2018 in MEDLINE, CINAHL, LILACS, EMBASE, the Cochrane Library, Econlit, Internet Documents in Economics Access Service, Public Affairs Information Service, Social Services Abstracts, Global Health CABI and CAB Abstracts (S2 Appendix). We searched grey literature, websites, asked experts, contacted authors and screened 299 included studies from relevant systematic reviews. There were no language limits.

Two independent reviewers screened titles and abstracts. Conflicts were discussed and resolved with VW or MG. All potentially eligible studies were retrieved and screened in duplicate in full text.

The first authors of all eligible studies were invited to join the Trialists’ Collaborative in December 2016. In case of no reply, we contacted all authors and their institutions. Data collection was closed in March 2018. Authors signed a data sharing agreement. IPD were checked for completeness. We verified any questions with authors. Data were prepared in an excel spreadsheet which included outcomes, covariates and study design variables. We replicated baseline and end of study analyses and calculated the standardized mean difference between the publication and our replication([13](#_ENREF_13)). To assess the influence of studies which we were unable to retrieve, we compared average findings for weight gain using aggregate data from our prior review ([5](#_ENREF_5)).

## Data analysis

Two independent reviewers collected details on participants, interventions, outcomes, study design, setting and duration (Table 1) using a pre-tested form.

The primary outcomes were weight (kilograms), height (centimetres), haemoglobin (g/L) and cognitive outcomes. We chose to use weight and height in kg and cm respectively because these would have the greatest precision to detect differences. To adjust for differences in importance of a given weight and height change for different ages, sex, anaemia and nutritional status, we adjusted for these factors in our model, as well as infection intensity of each STH. We did not include harms since these have been assessed in previous reviews and are not considered serious([3](#_ENREF_3)). We intended to assess plasma ferritin but only six studies reported this outcome, thus we decided not to conduct these analyses which the advisory board felt could be misleading.

We used multiple imputation for missing data, based on the assumption that data are missing at random([9](#_ENREF_9), [14](#_ENREF_14), [15](#_ENREF_15)) For studies with less than 50% missing data, we used multiple imputation for baseline and endline and created five complete datasets using Proc MI in SAS9.4/STAT (SAS Institute Inc., Cary, NC, USA). All model estimates and standard errors were obtained by fitting the model to each of these five imputed datasets and aggregating results across them using Rubin’s Rule which incorporates uncertainty due to imputation. Proc MIANALYZE in SAS 9.4/STAT was used to obtain the overall estimates across imputed datasets. We used WHO Anthro 3.2.2 to calculate BMI-for-age, and height-for-age z-scores. Anaemia was defined according to age and sex using WHO standards and corrected for altitude, if needed([16](#_ENREF_16)).

Risk of bias was appraised by outcome with the Cochrane Risk of Bias tool in duplicate. A funnel plot was constructed for comparisons with more than 10 studies.

We used a frequentist approach for random-effects NMA. The covariates were identified with the advisory group: age, sex, baseline weight, height, haemoglobin, and infection intensity. Random effect General Linear Mixed Models (GLMM) was conducted with two random intercepts considered in the model: random effect 'trial' accounts for the response variables of patients within a given trial being correlated; and random effect 'Patient's clusters' which accounts for the correlation of responses between any patients from the same clusters (such as villages, schools or households) within a given trial. We expected a connected network of trials to allow direct and indirect comparisons based on our previous review ([5](#_ENREF_5)). We used the GLIMMIX procedure in SAS 9.4/STAT (SAS Institute Inc., Cary, NC, USA) for the GLMM NMA, considering models that account for multi-arm trials and adjust for covariates. Results are summarized as point estimates with 95% confidence intervals for the outcomes of weight (kg), height (cm), and haemoglobin (g/L). Data were analyzed as intention to treat.

The transitivity assumption was assessed by comparing distribution of effect modifiers for each comparison([8](#_ENREF_8)). The evidence network was designed with the advisory board, research team and trial authors based on clinical judgment and other evidence. The consistency assumption was assessed by evaluating the heterogeneity of direct comparisons (using visual inspection of forest plots and I2)([17](#_ENREF_17)) and comparing the effect estimates for direct evidence (aggregate), direct evidence (IPD) and indirect + direct evidence (NMA).

We planned subgroup analyses across *a priori* defined variables of individual-level baseline intensity of infection with *A. lumbricoides, T. trichiura* and hookworm, stunting, undernutrition, anaemia, age, sex, and socioeconomic status([12](#_ENREF_12)).

We conducted planned sensitivity analyses restricting to studies with low risk of bias for allocation concealment and without imputation (i.e. complete case analysis).

We developed a summary of findings table for STH deworming vs. placebo, and assessed GRADE certainty for each outcome([18](#_ENREF_18)).

We met with our advisory board in November 2016, July 2017 and March 2018. Trial authors met twice to discuss results (November 2017, March 2018). This study was approved by the Bruyère Research Institute and SickKids research ethics boards.

The evidence network and composition of the nodes were decided based on clinical and methodological reasons with our advisory board([19](#_ENREF_19)).

# Results

## Search and study identification

We screened 14034 titles and abstracts. 340 studies were screened in full-text. 55 studies were considered eligible (Fig 1). Reasons for exclusion at full-text were not randomized or quasi-randomized trial (n=262), no baseline infection intensity (n=14) or too short (9 studies were <4 months duration) (S3 Appendix).

We obtained data from only two trials of deworming for schistosomiasis (2/14 studies). The advisory board decided not to analyze these since results would not be representative of the totality of the evidence.

**Fig 1. PRISMA Flow chart of searches up to March 27, 2018**

We obtained data for 79% of children (31,945 of 40,525) randomized to eligible studies of STH deworming (19 of 42 eligible published trials). For the 22 studies that we could not retrieve, reasons for not providing data were non-response (n=7 studies), lost data (n=10 studies) and administrative issues (n=5). For studies conducted before 2000, we received only 4 of 19 STH deworming studies (21%).

## Comparison of studies retrieved with those not retrieved

We used aggregate data from our previous Campbell review to compare studies of deworming for STH vs. placebo for which we received data compared to those for which data was not received. The effects on weight gain was 0.02 kg (-0.04 to 0.08) for studies received vs. 0.17 kg (-0.11, 0.44) for those not received (interaction test for subgroup differences: p=0.31). Studies for which we did not receive IPD had a larger pooled effect size on weight gain with a wider confidence interval.

## Description of studies

The studies were conducted globally (Table 1; Fig 2; S1 Table). Children were a median of 10.8 years old at enrolment (interquartile range: 8.8 to 13.0) according to IPD, median study duration was 12 months (range 4 months to 45 months), median frequency of deworming was every 4 months (range: 2 to 8 months), and 7 out of 19 studies gave a single dose of deworming.

**Table 1: Characteristics of included studies**

| **Study** | **Country** | **Design** | **Type of Cluster (number of clusters)** | **Sample size (children per cluster)** | **Age range**  **(years)**  **Recruitment** | **Interventions** | **Frequency of deworming, Study duration** | **Compliance with STH deworming** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Beasley 1999 | Tanzania | RCT  SAT |  | 357 | 7 to 12  community | 1. Albendazole + Praziquantel  2. Placebo | 5 months,  5 months | Not reported |
| Beasley Tanbase 1999  (thesis) | Tanzania | RCT  SAT |  | 217 | 6 to 15  community | 1. Albendazole + Praziquantel + iron,  2. Placebo | 4 months,  4 months | 100% (full course of 10 doses of iron given on a daily basis was received over 4 weeks due to absenteeism). |
| Ebenezer 2013 | Sri Lanka | cRCT  MDA | Schools  (100) | 1570  (20) | 8 to 15  schools | 1. Mebendazole + iron tablet  2. Placebo | 6 months,  6 months | 94-98% with deworming, 80% with iron tablets |
| Friis 2003 | Kenya | RCT  MDA |  | 915 | 8 to 18  schools | 1. Albendazole + praziquantel  2. Albendazole + praziquantel + micronutrient tablet  3. micronutrient tablet  4. Placebo | 8 months,  8 months | Not reported |
| Huong 2007 | Vietnam | RCT  MDA |  | 426 | 6 to 9  schools | 1. Mebendazole + unfortified noodles  2. Mebendazole + iron fortified noodles  3. Mebendazole + iron tablet 4. iron-fortified noodles  5. Placebo + unfortified noodles | 3 months,  6 months | 93-99% consumed noodles and iron tablets |
| Liu 2017 | China | cRCT  MDA | Townships (112) | 2179  (20) | 9 to 12  Town-ships | 1. Albendazole  2. Control (no deworming) | 6 months,  12 months | 52% fully compliant, 76% took at least one out of two albendazole pills in both rounds |
| Ndibazza 2013 | Uganda | RCT  MDA |  | 2016 | 1 to 2  community | 1. Albendazole  2. Placebo | 3 months,  45 months | 19-22% received all 16 doses (over 5 years) |
| Nga 2009 | Vietnam | RCT  MDA |  | 510 | 6 to 8  schools | 1. Albendazole + unfortified biscuit  2. Albendazole + micronutrient fortified biscuit  3. micronutrient fortified biscuit  4. Placebo + unfortified biscuit | 4 months,  4 months | 94% compliant with consuming biscuits |
| Olds 1999 | Kenya  (note: data from Kenya site, not from China or Philippines sites) | RCT  MDA |  | 371 | 6 to 17  villages | 1. Albendazole  2. Praziquantel  3. Albendazole + Praziquantel  4. Placebo | 6 months,  12 months | Not reported |
| Rohner 2010 | Côte d’Ivoire | RCT  MDA |  | 311 | 6 to 14  schools | 1. Iron fortified biscuits  2. Albendazole + Praziquantel  3. IPT  4. Albendazole + Praziquantel + Iron fortified biscuits  5. Albendazole + Praziquantel + IPT  6. IPT + Iron fortified biscuits  7. Albendazole + Praziquantel + IF + IPT  8. Placebo + unfortified biscuits | 3 months,  6 months | 94% for anthelminthics |
| Solon 2003 | Philippines | RCT  MDA |  | 831 | 6 to 17  schools | 1. Albendazole + unfortified beverage  2. Albendazole + micronutrient fortified beverage  3. micronutrient fortified beverage  4. Placebo + unfortified beverage | 4 months,  4 months | Not reported |
| Stoltzfus 1997 | Tanzania | cRCT  MDA | Schools  (12) | 4034 | 5 to 19  schools | 1. Mebendazole (2/year)  2. Mebendazole (3/year)  3. Placebo | 6 months (1)  4 months (2),  12 months | Not reported |
| Stoltzfus 2004 | Tanzania | cRCT  MDA | House-holds (451) | 463 | 0.5 to 6  House-holds | 1. Mebendazole (high)  2. Mebendazole (high) + iron supplement  3. iron supplement  4. Placebo | 3 months,  12 months | Not reported |
| Yap 2014 | China | RCT  SAT |  | 194 | 9 to 12  schools | 1. Albendazole  2. Placebo | 6 months,  6 months | 92%, field investigators directly observed consumption |
| Kirwan 2009 | Nigeria | RCT  MDA |  | 1367 | 1 to 4  Pre-school in villages | 1. Albendazole  2. Placebo | 4 months,  14 months | Not reported. Consumption was directly observed |
| Hall 2006 | Vietnam | cRCT  MDA | Schools  (80) | 2916 | 8 to 9  schools | 1. Albendazole + vitamin A  2. Placebo + vitamin A | 6 months,  12 months | Not reported |
| Miguel 2004 | Kenya | cRCT  MDA | Schools  (75) | 15881 | 6 to 18  schools | 1.Albendazole  2. Albendazole + Praziquantel  3. Control | 6 months,  3 years | 96% |
| Rousham 1994 | Bangladesh | cRCT  MDA | Villages  (7) | 124 | 2 to 6  villages | 1. Mebendazole  2. Placebo | 2 months,  12 months | Not reported |
| Wiria 2013 | Indonesia | cRCT  MDA | House-holds (954) | 1854 | 2 to 16  villages | 1. Albendazole  2. Placebo | 3 months,  21 months | 78% with antheminthic |

Notes: MDA: Mass drug administration, SAT: Screen and Treat, cRCT: cluster randomized trial, RCT: randomized controlled trial

References of included studies in S3 Appendix Additional References in Supporting Information

**Fig 2: Countries where included studies were conducted**

For nutritional status, 16% of the children were below -2 z-scores for BMI-for-age, 33% were stunted and 50% were anaemic (Table 2). The prevalence of infection was 45% for *A. lumbricoides* (31% light, 13% moderate and 1% heavy infection intensity), 52% for *T. trichiura* (38% light, 14% moderate and 0% heavy) and 45% for hookworm (38% light, 5% moderate and 2% heavy infection intensity). For the studies which we received, five studies had greater than 50% missing data (S2 Table).

**Table 2: Characteristics of children in the 14 studies used for the base case analyses**

|  |  |  |
| --- | --- | --- |
| **Variable** | **Distribution** | **sample size** |
| BMI-for-age | ≤ - 2 | 2259 |
| (z-score) | > -2 | 11696 |
| Height-for-age | ≤ -2 | 4609 |
| (z-score) | > -2 | 9346 |
| Hookworm | 0 (none) | 7700 |
| (epg) | 1-384 | 3169 |
|  | >384 | 3086 |
| *T. trichiura* | 0 (none | 6729 |
| (epg) | 1-288 | 3656 |
|  | >288 | 3570 |
| *A. lumbricoides* | 0 (none) | 7738 |
| (epg) | 1-1776 | 3116 |
|  | >1776 | 3101 |
| Anyworm\*\* | 0 | 4721 |
|  | 1 | 6047 |
|  | 2 | 3187 |
| Anaemia\*\*\* | No | 7300 |
|  | Yes | 6655 |
| Age at time of treatment | < 5 years | 2448 |
|  | ≥5 years | 11507 |
| Sex | Male | 7298 |
|  | Female | 6657 |

\*epg: eggs per gram of stool,

\*\*“Anyworm” is a variable indicating children with no detected STH infection of any type of STH, light intensity using WHO cut-offs for each type of STH, or moderate or heavy infection intensity for any type of STH,

\*\*\*Anaemia cut points defined on the basis of age and sex using WHO guidelines([16](#_ENREF_16))

## Risk of bias

Overall risk of bias was low. The risk of attrition bias was high in 7 of 19 studies (Fig 3). A funnel plot for STH deworming vs. placebo did not show evidence of publication bias. We obtained unpublished data on nutritional outcomes from 8 studies suggesting selective outcome reporting is an issue in this area.

**Fig 3: Risk of bias graph**

## Evidence network

We decided on the evidence network of six nodes as the base case with our advisory board based on clinical and methodological reasons ([20](#_ENREF_20)). This is described as a deviation from our protocol (S1 Appendix) since the method for developing the evidence network was not described in our *a priori* protocol([12](#_ENREF_12)). We tested whether our findings were robust to using the full evidence network which consisted of 18 nodes for 19 RCTs (S1 Fig). The network of six nodes grouped all deworming for STH (of any frequency) together, all micronutrients together and all deworming for schistosomiasis together. The six nodes were: 1) placebo, 2) STH deworming alone, 3) Deworming for schistosomiasis with or without STH deworming, 4) Deworming for schistosomiasis with any type of iron or micronutrient, 5) STH deworming with any type of micronutrient or iron, and 6) iron or micronutrient alone (Fig 4). We analyzed and compared results for both the six-node and full evidence network.

**Fig 4: Evidence network, six-node**

## Main analysis

In our IPD NMA evidence network, the results for weight of STH deworming alone vs. placebo was 0.01 kg (95%CI: -0.08, 0.11) (for other comparisons, Fig 5). The effect on height for STH deworming alone vs. placebo was 0.09 cm (95%CI: -0.08 to 0.27) (see Fig 5). For haemoglobin, the effect of STH deworming alone vs. placebo was 0.32 g/L (95%CI: -0.63, 1.26). When deworming for STH was combined with deworming for schistosomiasis or iron/micronutrients, there were increases in haemoglobin vs. placebo. For STH and micronutrients vs. micronutrients alone, the effect was 0.70 g/L (95%CI: -0.72, 2.11; Fig 5). For cognition, studies were not pooled since the advisory board felt that measures were too different in linguistic translation and implementation (S3 Table for measures). For STH deworming alone vs. placebo, there were no clinically meaningful effects observed for short-term attention, school achievement or motor development. One study found improved short-term attention for micronutrient fortification and STH deworming compared to placebo([21](#_ENREF_21)). These cognition analyses were limited by few participants.

**Fig 5: Main effects on weight (in kg), height (in cm) and haemoglobin (in g/L)**

The transitivity and consistency assumptions were considered plausible based on assessing heterogeneity, consistency of direct and indirect estimates, and distribution of covariates across each comparison (S4 Table). GRADE quality was assessed as moderate for all outcomes for STH vs placebo, downgraded because we obtained only 46% of eligible studies (79% of randomized children).

Analysis of effects on infection prevalence showed variable effectiveness of the different combinations of STH deworming and schistosomiasis deworming on *A. lumbricoides*, *T. trichiura* and hookworm (S2-S4 Figs).

## Subgroup analyses and effect modification

We planned to use WHO cut-offs for intensity of infection but there were too few children with moderate and high intensity STH infection (less than 13% for each STH) for the network meta-analysis model. Thus, we decided with the Advisory Board and Trialists Collaborative *post-hoc* to use two methods to assess the role of infection intensity: 1) subgroup analysis for direct evidence; and 2) NMA using lower cut-offs based on median infection intensity to allow assessment of the gradient of effect. For the analysis of subgroup effects using direct evidence from trials, for STH deworming compared to placebo, the effect for children with moderate or heavy intensity *A. lumbricoides* infections (WHO cut-offs) was 0.12 kg (95%CI: -0.05, 0.28); for moderate or heavy intensity *T. trichiura* infections, the effect was 0.11 kg (-0.14, 0.35) and for moderate or heavy intensity hookworm infections, the effect on weight was -0.53 kg (95%CI: -2.09, 1.03). No subgroup tests for interaction were statistically significant (see S5-S13 Figs for weight, height and hemoglobin across each type of STH). However, there were larger effects on weight gain for children with moderate or heavy intensity infections of *A. lumbricoides* and *T. trichiura* than children with light or no detected infection.

For the second approach, analysis using the IPD NMA evidence network, tests for interaction were not statistically significant for any subgroup effects for any comparisons across: age, sex, BMI-for-age, height-for-age, anaemia and intensity of any type of STH infection (using cut-offs for intensity of infection for each STH based on the median distribution). There was imprecision for these effect modification analyses across STH intensity. The 95% confidence intervals included potentially important effects of up to 460 grams for weight and 7 g/L for haemoglobin for higher intensity infections of *A. lumbricoides*, *T. trichiura* or hookworm (defined according to the median of the distribution) for STH deworming vs. placebo (Table 3).

**Table 3: Effect modifier analysis across STH infection intensity for STH deworming vs. placebo**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Level** | **Weight (kg)** | **Height (cm)** | **Haemoglobin (g/L)** |
| *A. lumbricoides* | No detected infection | 0.00(-0.11,0.12) | 0.07(-0.14,0.27) | 0.48(-0.69,1.66) |
|  | Lighter intensity (1-1776 epg) | 0.07(-0.13,0.27) | 0.25(-0.14,0.63) | -0.10(-1.75,1.55) |
|  | Higher intensity (>1776 epg) | 0.08(-0.13,0.29) | 0.04(-0.22,0.30) | 0.03(-2.08,2.14) |
| Hookworm | No detected infection | 0.02(-0.09,0.13) | 0.06(-0.13,0.26) | 0.07(-0.92,1.06) |
|  | Lighter intensity (1-384 epg) | 0.05(-0.12,0.23) | 0.20(-0.16,0.55) | -0.04(-1.84,1.77) |
|  | Higher intensity (>384 epg) | 0.16(-0.13,0.46) | 0.20(-0.13,0.52) | 3.58(0.13,7.02) |
| *T. trichiura* | No detected infection | -0.01(-0.12,0.10) | 0.02(-0.18,0.22) | 0.17(-1.01,1.35) |
|  | Lighter intensity (1-288 epg) | 0.04(-0.11,0.20) | 0.30(-0.04,0.64) | 0.24(-1.23,1.71) |
|  | Higher intensity (>288 epg) | 0.17(-0.06,0.41) | 0.07(-0.20,0.34) | 1.33(-1.14,3.81) |

Note: epg: eggs per gram

## Sensitivity analyses

The main effects for each outcome were robust to six sensitivity analyses: 1) unadjusted analysis, 2) complete case analysis with base case studies (n=14), 3) complete case analysis with 5 additional studies that had >50% missing data, 4) studies at low risk of bias, 5) full evidence network with 18 nodes, and 6) restricting to studies with a larger effect on reducing STH infection prevalence.

## Updating prior meta-analyses with new IPD

We decided post-hoc to compare our results with prior meta-analyses and update prior meta-analyses with previously unpublished data on weight. In comparison to the meta-analysis by Croke et al, when we add data from this IPD to the aggregate data from our previous Campbell review([5](#_ENREF_5)), our effect estimate for weight is comparable for both fixed and random effects meta-analyses, though there are difference in the studies we included (S5 Table). When we add all studies from Croke et al to our prior meta-analysis with data from three previously unpublished studies on weight, the effect on weight is 0.10 kg (05%CI: 0.03 to 0.17). In comparison to two prior Cochrane([4](#_ENREF_4)) and Campbell([5](#_ENREF_5)) reviews, our findings are similar, with a smaller effect size for weight and height (S6 Table). We conducted *post-hoc* meta-regression analyses, using aggregate data from all studies included in our prior systematic review as well as previously unpublished data on weight from this review([5](#_ENREF_5)). There was no statistically significant effect of year of publication, *T. trichiura* or *A. lumbricoides* prevalence. Hookworm prevalence was positively associated with weight gain (p=0.014; Fig 6).

**Fig 6: Meta-regression analyses using all STH deworming vs. placebo studies**

# Discussion

A central issue of the debate about the effects of deworming on child nutritional and cognitive outcomes has been the difficulty in detecting effects from averages across populations where many children are uninfected or lightly infected and thus unlikely to benefit from deworming. Thus the added value of our study is the assessment of effect modification using individual level data. Analysis of individual level data for children with moderate or heavy intensity infections show that deworming may increase weight in children with moderate to heavy intensity infections of *A. Lumbricoides* or *T. trichiura* (but not hookworm) (very low certainty). These analyses did not show a statistically significant relationship for any other covariates for the effect of deworming on weight, height, hemoglobin or cognition in our network meta-analysis; covariates were age, anaemia, height for age, BMI for age and infection intensity for each type of STH according to the median of the distribution. These effect modification analyses are considered very low certainty since they are based on subgroup analyses and are imprecise. It is uncertain whether these findings would apply to children with heavy intensity infections since these represent less than 20% of the children in these analyses.

Secondly, our network meta-analysis approach allows the comparison of effects for deworming for STH when combined with micronutrients, iron or deworming for schistosomiasis. Combining STH deworming with micronutrients or iron was more effective than placebo for improving haemoglobin, but not more effective than micronutrients or iron alone. Combinations with praziquantel were also more effective at improving hemoglobin than STH deworming alone. There were little to no effects on short-term attention, school performance or development in individual studies, but these were limited by imprecision.

Thirdly, we updated previous meta-analyses by adding previously unpublished data obtained from authors for this review. These analyses reinforce the findings of population-level small effects on average for weight. This included three previously unpublished estimates for weight. This analysis replicated estimates of three prior systematic reviews of an average effect size on weight of about 100 grams and showed that this effect size was not related to the year of publication.

The findings are based on trials that have an overall low risk of bias, and main effects were robust to restricting to the lowest risk of bias studies. We considered the assumptions of transitivity and consistency for network meta-analysis were plausible based on our analyses.

In 2010, the prevalence of all STH infections was below 30% for all regions of the world for each STH which is somewhat lower than the average prevalence of 46% in our sample([1](#_ENREF_1)). These averages obscure the fact that some areas may have very high prevalence and heavy intensity infections. We expect that the average effects of about 100 grams on weight may apply to areas with similar infection prevalence and intensity levels to children in this analysis but cannot be assumed to apply to areas where the intensity of infection is much higher.

Croke and colleagues([6](#_ENREF_6)) proposed that the prior Cochrane review was under-powered to detect effects which could be considered cost-effective. With 31,945 children and 19 studies, our current analysis has over 90% power to detect an average effect size of 0.1 kg in the presence of moderate heterogeneity for the comparison of STH deworming vs. placebo([22](#_ENREF_22), [23](#_ENREF_23)) . Croke et al argued that the average effect size they found of 0.13 kg was cost-effective based on dividing the cost of $0.60 for two annual treatments of deworming by the weight gain, equating to $4.48/kg which is far less than the comparable cost per kg of school meals of $112 to $252/kg([24](#_ENREF_24)). We consider the average effect size, based on the totality of evidence, not just the IPD analysis, of 100 grams, to be of small practical importance for the typical child in these deworming studies of 7-10 years of age, who gains approximately 2 kg per year based on WHO annual growth charts. For children with moderate or heavy intensity *A. lumbricoides* infections, the effect on weight was 0.12 kg (95%CI: -0.05 to 0.28) which includes effect sizes of up to 280 grams which may be of importance to younger and more vulnerable children. This is smaller than effects of other nutritional programs such as school feeding which increases weight gain on average at a population level by about 0.39 kg annually([25](#_ENREF_25)). Our systematic review cannot predict outcomes or cost-effectiveness for chemoprophylaxis where intensity of infection is very heavy, since less than 2% of our sample had heavy intensity infections according to WHO cutoffs.

Strengths are a comprehensive search and transparent methodology described in an *a priori* protocol. We included an expert advisory board with expertise in nutrition, parasitology, economics and methodology and a trialists’ collaborative. We were able to obtain data from 79% of children randomized to eligible deworming studies. We accounted for differences in baseline nutritional status, age, sex, anaemia and infection intensity and also assessed possible effect modification across these factors. The results were robust to a range of sensitivity analyses including complete case analysis and restricting to studies at low risk of bias. We were able to include data from studies which may not have been designed or powered for these outcomes.

A limitation of our analyses is that we were unable to retrieve 22 out of 41 eligible studies (which included 8,580 children), despite, in most cases, the good will of the original trialists, due to inability to locate the data, administrative barriers to sharing data or lost datasets. Another limitation is that only 2% of children in these studies had heavy intensity infections defined according to WHO cut-offs, which limited our assessment of effects across intensity, in particular for children with heavy intensity infections. These analyses across intensity of infection are limited by measurement issues since WHO cut-offs for intensity are arbitrary and their importance may vary according to different contexts. Also, infection intensity was assessed by different methods including Kato-Katz, PCR and other techniques which have different measurement properties. The median study duration of 12 months limits any inferences about long-term effects of mass deworming. Our analysis included 7 studies with single dose of STH deworming which may have been influenced by re-infection in endemic areas. We were unable to adjust for socioeconomic status, water/hygiene environment, presence of schistosomiasis or malaria since there were insufficient details across studies.

# Conclusions

For children with moderate or heavy intensity infections (using WHO cut-offs), deworming may have small effects on weight but not height or hemoglobin (very low certainty evidence). Effects of deworming are uncertain in children with heavy intensity infections. Based on the totality of evidence from three prior systematic reviews and new data from IPD previously unpublished, average effects of mass deworming on child nutritional status and cognition are small at the population level (moderate certainty), thus needs to be complemented by other public health measures. To maximize the societal benefit of research, we strongly support the Open Science movement to reduce limitations in data retrieval for analyses such as these which aim to improve the lives of the most vulnerable populations.

# Acknowledgements

We would like to thank Celia Holland for being part of our Advisory board and providing comments on interim results. We would like to thank Bishop Beasley, Nilanthi de Silva, Rebecca Stoltzfus and James Tielsch for contributing data. We would like to thank Jessica Trawin, Christine Mathew, who contributed to data collection and preparation; and Jordan Bernick who contributed to the analysis. We would like to thank anonymous peer referees who provided constructive comments that helped us improve on an earlier version of this paper. We would like to acknowledge the Campbell Collaboration International Development Coordinating group which managed the peer review process for the protocol and final review. This systematic review will be co-published with the Campbell Collaboration.

# References

1. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. Parasites & vectors. 2014;7(1):37.

2. Bundy DA, Appleby LJ, Bradley M, Croke K, Hollingsworth TD, Pullan R, et al. 100 Years of Mass Deworming Programmes: A Policy Perspective From the World Bank's Disease Control Priorities Analyses. Advances in parasitology. 100: Elsevier; 2018. p. 127-54.

3. World Health Organization. Guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups: World Health Organization; 2017 [September 12, 2018]. Available from: <http://apps.who.int/iris/bitstream/handle/10665/258983/9789241550116-eng.pdf;jsessionid=EB785E884EDF96CCC9826D3F9AAE0912?sequence=1>.

4. Taylor‐Robinson DC, Maayan N, Soares‐Weiser K, Donegan S, Garner P. Deworming drugs for soil‐transmitted intestinal worms in children: effects on nutritional indicators, haemoglobin, and school performance. Cochrane Database of Systematic Reviews. 2015(7).

5. Welch V, Ghogomu E, Hossain A, Awasthi S, Bhutta Z, Cumberbatch C, et al. Deworming and Adjuvant Interventions for Improving the Developmental Health and Well-being of Children in Low- and Middle-income Countries: A Systematic Review and Network Meta-analysis. Campbell Systematic Reviews. 2016;2016:7.

6. Croke K, Hicks JH, Hsu E, Kremer M, Miguel E. Does mass deworming affect child nutrition. Meta-analysis, Cost-Effectiveness, and Statistical Power Natl Bur Econ Res Work Pap Ser. 2016;22382.

7. Dagne GA, Brown CH, Howe G, Kellam SG, Liu L. Testing moderation in network meta‐analysis with individual participant data. Statistics in medicine. 2016;35(15):2485-502.

8. Salanti G. Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research synthesis methods. 2012;3(2):80-97.

9. Debray TP, Schuit E, Efthimiou O, Reitsma JB, Ioannidis JP, Salanti G, et al. An overview of methods for network meta-analysis using individual participant data: when do benefits arise? Statistical methods in medical research. 2018;27(5):1351-64.

10. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Annals of internal medicine. 2015;162(11):777-84.

11. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. Jama. 2015;313(16):1657-65.

12. Welch V, Ghogomu E, Hossain A, Arora P, Cousens S, Gaffey M, et al. Mass deworming for improving health and cognition of children in endemic helminth areas: a systematic review and individual participant data network meta-analysis. Campbell Systematic Reviews 2018;2018:4.

13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Statistics in medicine. 2009;28(25):3083-107.

14. Groenwold RH, Moons KG, Vandenbroucke JPJC. Randomized trials with missing outcome data: how to analyze and what to report. 2014;186(15):1153-7.

15. Jakobsen JC, Gluud C, Wetterslev J, Winkel PJBmrm. When and how should multiple imputation be used for handling missing data in randomised clinical trials–a practical guide with flowcharts. 2017;17(1):162.

16. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity 2011 [September 12, 2018]. Available from: <http://www.who.int/vmnis/indicators/haemoglobin/en/>.

17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in medicine. 2002;21(11):1539-58.

18. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. Bmj. 2014;349:g5630.

19. Giovane CD, Vacchi L, Mavridis D, Filippini G, Salanti GJSiM. Network meta‐analysis models to account for variability in treatment definitions: application to dose effects. 2013;32(1):25-39.

20. Rouse B, Chaimani A, Li TJI, medicine e. Network meta-analysis: an introduction for clinicians. 2017;12(1):103-11.

21. Nga TT, Winichagoon P, Dijkhuizen MA, Khan NC, Wasantwisut E, Wieringa FT. Decreased parasite load and improved cognitive outcomes caused by deworming and consumption of multi-micronutrient fortified biscuits in rural Vietnamese schoolchildren. The American journal of tropical medicine and hygiene. 2011;85(2):333-40.

22. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychological methods. 2001;6(3):203.

23. Tiebel J. Calculation of statistical power in meta-analysis OSF2008 [Available from: <https://doi.org/10.17605/OSF.IO/W4XRS>

24. Galloway R, Kristjansson E, Gelli A, Meir U, Espejo F, Bundy D. School feeding: outcomes and costs. Food and Nutrition Bulletin. 2009;30(2):171-82.

25. Kristjansson E, Robinson V, Petticrew M, MacDonald B, Krasevec J, Janzen L, et al. School feeding for improving the physical and psychosocial health of disadvantaged elementary school children. Cochrane Database Syst Rev. 2007(1):CD004676.

# Supporting Information

S1 Table: Characteristics of included studies child and setting characteristics (n=19)

S2 Table: Number and percentage of missing values at baseline and endline of outcome variables and covariates by eligible study

S3 Table: Cognition outcomes, as defined by authors

S4 Table: Example of assessment of consistency and heterogeneity for comparison of deworming for STH vs placebo

S5 Table: Comparison of Croke et al 2016 meta-analysis to the totality of study estimates in Welch et al 2016 and Welch et al 2018

S6 Table: Comparison of 3 prior systematic reviews, this review, and totality of evidence

S1 Fig: Full evidence network, 18 nodes, 19 RCTs

S2 Fig: Effect of deworming on *A. lumbricoides* prevalence

S3 Fig: Effect of deworming on T*. trichiura* prevalence

S4 Fig: Effect of deworming on hookworm prevalence

S5 Fig: Direct evidence analysis across *A. lumbricoides* prevalence, weight (kg)

S6 Fig: Direct evidence analysis across *T. trichiura* prevalence, weight (kg)

S7 Fig: Direct evidence analysis across hookworm prevalence, weight (kg)

S8 Fig: Direct evidence analysis across *A. lumbricoides* prevalence, height (cm)

S9 Fig: Direct evidence analysis across *T. trichiura* prevalence, height (cm)

S10 Fig: Direct evidence analysis across hookworm prevalence, height (cm)

S11 Fig: Direct evidence analysis across A*. lumbricoides* prevalence, hemoglobin (g/L)

S12 Fig: Direct evidence analysis across *T. trichiura* prevalence, hemoglobin (g/L)

S13 Fig: Direct evidence analysis across hookworm prevalence, hemoglobin (g/L)

S1 Appendix: Deviations from protocol

S2 Appendix: Search strategy

S3 Appendix: Additional references and excluded studies

# Figures

## Fig 1: PRISMA Flow chart of searches up to March 27, 2018



Note: number of STH studies and Schistosomiasis studies adds to 56 (not 55) since Olds 1999 study is counted as both STH deworming and schistosomiasis deworming because it is a factorial trial.

## Fig 2: Countries where included studies were conducted

S:\BRI Investigators\Welch\Deworming IPD\PLOSNTD\Fig 2_new.tif

\*Note: Olds 1999 is a single study which was carried out in three sites (Kenya, China and the Philippines); we only received IPD for the Kenya site.

Figure source: <https://pxhere.com/en/photo/1262215>, CC0 Public Domain

Fig 3: Risk of bias graph




****

Fig 4: Evidence network, six nodes




Note: MCN: Micronutrients; PZQ: praziquantel; STH: Soil transmitted helminths deworming

## Fig 5: Main effects on weight (in kg), height (in cm) and haemoglobin (in g/L)

****

Notes: STH: soil-transmitted helminth deworming, PZQ: praziquantel; MCN: micronutrients in any form (supplements or fortified beverage or food); iron in any form (supplement or fortification)

## Fig 6: Meta-regression analyses using all STH deworming vs. placebo studies



# Note: uses aggregate data from all studies Funding support

This research was funded by the Bill and Melinda Gates Foundation

**Role of funder/sponsors:** The funder had no role in the analysis, interpretation or decision to publish.

# Competing Interests

Dr. Welch is editor in chief of the Campbell Collaboration. The protocol for this systematic review was registered with the Campbell Collaboration, where the peer review process was handled by an independent editor.

Dr. Hossain has nothing to disclose.

Dr. Ghogomu has nothing to disclose.

Dr. Riddle has nothing to disclose.

Ms. Gaffey has nothing to disclose.

Dr. Arora has nothing to disclose.

Mr. Dewidar has nothing to disclose.

Dr. CHEN has nothing to disclose.

Dr. Abdus Salam has nothing to disclose.

Prof Cousens has nothing to disclose.

Dr. Bhutta has nothing to disclose.

Dr. Wells has nothing to disclose.

Dr. Black has nothing to disclose.

Dr. Hollingsworth has nothing to disclose.

Dr. Sue Horton has nothing to disclose.

Dr. Tugwell has nothing to disclose.

Dr. Bundy has nothing to disclose.

Dr. Castro has nothing to disclose.

Dr. Friis reports grants from ARLA Food for Health Center, grants from Danish Dairy Research Foundation, grants from Nutriset, outside the submitted work.

Dr. Elliott reports grants from Wellcome Trust, during the conduct of the study

Dr. King reports grants from World Health Organization for work included in the study

Dr. Le Thi has nothing to disclose.

Dr. LIU reports grants from International Initiative for Impact Evaluation, grants from National Natural Science Foundation of China, during the conduct of the study.

Dr. Rohner has nothing to disclose.

Dr. Rousham has nothing to disclose.

Dr. Sartono has nothing to disclose.

Dr. Steinmann has nothing to disclose.

Dr. Supali has nothing to disclose.

Dr. Webb has nothing to disclose.

Dr. Wieringa has nothing to disclose.

Dr. Winnichagoon has nothing to disclose.

Dr. Yazdanbakhsh has nothing to disclose.